Quarterly ResultMay 7, 2026, 04:03 PM
Tectonic Therapeutic Q1 Net Loss $25.2M; TX45/TX2100 Trials Advance; Cash to Q4 2028
AI Summary
Tectonic Therapeutic reported a Q1 2026 net loss of $25.2 million, an increase from $15.9 million in Q1 2025. The company made significant progress in its clinical pipeline, with TX45 APEX Phase 2 enrollment nearing completion and topline results expected late Q4 2026 or early Q1 2027. TX2100 advanced into a Phase 1a trial for HHT, with topline results anticipated by end of Q3 2026, and the TX45 ALPINE Phase 2 trial for PH-ILD was initiated. The company strengthened its leadership with two new board appointments and reported $236.9 million in cash and cash equivalents, providing a runway into Q4 2028.
Key Highlights
- TX45 APEX Phase 2 enrollment nearing completion; topline results expected late Q4 2026 or early Q1 2027.
- TX2100 Phase 1a trial for HHT initiated; topline results expected by end of Q3 2026.
- TX45 ALPINE Phase 2 clinical trial initiated in PH-ILD in February 2026.
- Appointed François Nader, M.D., as Chair of the Board and Jessica Chutter as independent director.
- Cash and cash equivalents were $236.9 million as of March 31, 2026.
- Cash runway is expected to extend into Q4 2028.
- Net loss for Q1 2026 was $25.2 million, compared to $15.9 million in Q1 2025.
- Research and development expenses increased to $20.9 million from $13.0 million YoY.